z-logo
Premium
The effect of a repeated immunoadsorption in patients with dilated cardiomyopathy after recurrence of severe heart failure symptoms
Author(s) -
Reinthaler Markus,
Empen Klaus,
Herda Lars R.,
Schwabe Anna,
Rühl Michael,
Dörr Marcus,
Felix Stefan B.
Publication year - 2015
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.21364
Subject(s) - medicine , immunoadsorption , ejection fraction , dilated cardiomyopathy , heart failure , cardiology , cardiomyopathy , cardiac function curve , hemodynamics , antibody , immunology
Background : In patients suffering from dilated cardiomyopathy (DCM), immunoadsorption with subsequent IgG substitution (IA/IgG) leads to an acute and prolonged improvement of hemodynamics and heart failure symptoms. However, some patients receiving IA/IgG experience recurrence of heart failure after an initial benefit. The aim of this study was to investigate whether a second IA/IgG treatment episode improves left ventricular systolic function and further mitigates heart failure symptoms in these patients. Methods : We retrospectively analyzed 15 DCM patients who experienced a significant improvement of LVEF (≥ 5% absolute or ≥ 20% relative) and heart failure symptoms (≥ 1 NYHA functional class) but a subsequent deterioration (decline in LVEF ≥ 5% absolute or ≥ 20% relative and NYHA worsening ≥1 class) after the first IA/IgG. These patients underwent a second IA/IgG treatment 41.7 ± 27.4 months after the first cycle. Follow up data were acquired 3–6 months after both IA/IgG treatments. Results : The first IA/IgG induced an improvement of LVEF from 33 ± 6.4% to 43.2 ± 7.9% ( P  < 0.001) and of mean NYHA functional class from 2.9 ± 0.26 to 1.8 ± 0.56 ( P  < 0.001). The second treatment was associated with a significant improvement in LVEF (from 29.7 ± 4.6% to 34.9 ± 8.3%, P  = 0.013) and NYHA functional class (2.87 ± 0.64 to 2.33 ± 0.72; P  = 0.02). This improvement was less pronounced compared to the first treatment with respect to both, LVEF ( P  = 0.09) and NYHA improvement ( P  = 0.04). Conclusion: In DCM patients, who experience a significant improvement of LVEF and heart failure symptoms after IA/IgG but a subsequent relapse during follow up, repeated IA/IgG may be considered. J. Clin. Apheresis 30:217–223, 2015. © 2014 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom